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Introduction: Hepatitis B virus (HBV) reactivation (so-called reverse seroconversion) is a rare but known complication
of hematopoietic stem cell transplantation, immunosuppressive therapy, or high-dose chemotherapy plus rituximab.
This event is linked to a treatment-related fall in titers of antibodies to hepatitis B surface antigen (HBsAb) below the
protective threshold level.
Case presentation: A 77-year-old Korean man diagnosed with primary amyloidosis was started on melphalan/
dexamethasone combination therapy. During treatment, laboratory indices of hepatic function suddenly deteriorated,
and he developed acute hepatitis through reverse HBV seroconversion, becoming positive for hepatitis B surface
antigen (HBsAg) and negative for HBsAb. HBV DNA was also detectable in serum to a profound extent. Normal liver
function was gradually restored during the course of antiviral therapy (entecavir).
Conclusions: HBV reactivation may lead to fatal liver disease in a significant percentage of patients. As a result,
physicians often screen for HBsAg and HBsAb prior to initiating chemotherapy, advising antiviral treatment in patients
seropositive for HBsAg, even in the absence of hepatitis B e antigen. Here, a case of HBV reactivation is described,
involving a patient given relatively low-dose chemotherapy (melphalan/dexamethasone) for primary amyloidosis.
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Instances of hepatitis B virus (HBV) reactivation (so-called
reverse seroconversion) have been reported after
hematopoietic stem cell transplantation or high-dose che-
motherapy plus rituximab and are seldom-observed conse-
quences of multiple myeloma. However, there are no known
published accounts of HBV reactivation following melpha-
lan/dexamethasone treatment of primary amyloidosis [1-5].
Case presentation
A 77-year-old Korean man presented to our hospital
with an axillary mass. The presence of amyloid in the
subsequent excisional biopsy prompted a bone marrow* Correspondence: sgpark@chosun.ac.kr
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studies, including computed tomography (CT). Ulti-
mately, a diagnosis of primary amyloidosis was rendered.
Despite the patient’s advanced age, melphalan/
dexamethasone combination therapy was elected. After
three cycles of this regimen, detectable masses grew
smaller and his serum kappa/lambda ratio normalized, so
treatment continued. However, serum levels of aspartate
aminotransferase (AST) and alanine aminotransferase
(ALT) rose precipitously after six cycles of therapy.
Our patient denied use of other medications (including
herbal or dietary supplements), smoking, or consumption
of alcohol, and there was no history of blood transfusion.
On physical examination, he was alert, with normal blood
pressure, pulse, and respiratory rate. No direct or rebound
tenderness of the abdomen was evident.ticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Figure 1 Changes of values of liver function tests and viral indicators.
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blood cell count, 2,720/mm3 (40.1% neutrophils, 43.5%
lymphocytes, 1.4% eosinophils); hematocrit, 10.6g/dL;
platelet count, 111,000/mm3; prothrombin time, 11.8
seconds; AST level, 454.1IU/L; ALT level, 496.3IU/L; total
bilirubin, 1.34mg/dL; direct bilirubin, 1.04mg/dL; albumin,
3.11g/d; alkaline phosphatase (ALP), 142U/L; gamma-
glutamyl transferase (rGTP), 126U/L; blood urea nitrogen
(BUN), 17.2mg/dL; and creatinine (Cr), 1.28mg/dL.
Prior to initiating chemotherapy, our patient had been
screened twice for hepatitis, testing negative for hepatitis
B surface antigen (HBsAg, 0.41S/Co) and positive for
antibodies to HBsAg (HBsAb, 55.0mIU/mL). No further
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Co) and loss of HBsAb (0.62mIU/mL) were documented.
Repeat testing generated the same results, so screening was
expanded to include hepatitis B envelope antigen (HBeAg,
negative (0.27S/Co)), antibodies to HBeAg (HBeAb, posi-
tive (0.02S/Co)), and antibodies to hepatitis B core antigen
(immunoglobulin M (IgM) HBcAb, negative (0.27S/Co);
immunoglobulin M (IgG) HBcAb, positive (2.2S/Co)).
A massive HBV DNA burden (67,322,328 copies/mL)
was also determined by real-time polymerase chain reac-
tion (PCR).
Given a lack of HBV vaccination by history, the pa-
tient’s baseline HBsAb positivity was attributed to innate
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antiviral treatment was then administered, gradually re-
storing normal liver function within three weeks. Five
months later, AST and ALT levels were 40IU/L and 12IU/L,
respectively. At this point, he also tested negative for
HBsAg and positive for HBsAb, with PCR-determined
HBV DNA level at 3,600 copies/mL (Figure 1, Table 1).
Continued chemotherapy for primary amyloidosis was de-
clined, and he died unexpectedly seven months later.
Discussion
HBV infection remains a major cause of acute and chronic
liver disease. According to the World Health Organization
(WHO), 350 to 400 million people worldwide suffer from
chronic HBV infection [6], with relatively greater preva-
lence in Korea (2 to 10%) [7]. Presence of HBsAb and
HBcAb is equated with resolution of infection and HBV
clearance. In addition to enabling viral clearance during
acute infection, immune reactivity to HBV antigens is also
responsible for disease pathogenesis [8].
Innate immunity is important in controlling HBV infec-
tion immediately after onset, generally limiting the spread
of infection and instigating an efficient adaptive immune re-
sponse. Organism-specific structures (for example, double-
stranded RNA and bacterial wall components) of pathogens
trigger pattern-recognition receptors (PRRs) to activate in-
nate immunity. The most important PRRs in viral infec-
tions are Toll-like receptors (TLRs), RNA helicases (such
as retinoic acid-inducible gene I (RIG-I) and melanoma
differentiation-associated gene 5 (MDA5)), and double-
stranded RNA-dependent protein kinase (PKR) [8,9].
Adaptive immunity is responsible for immunity to
HBV infection conferred by vaccine administration. Rou-
tine HBV vaccination at birth is recommended for a
number of reasons. Approximately 90% of infants born
to HBV-infected mothers will acquire the infection at
birth; and 30 to 50% of infected youths <5 years of age
become chronic HBV carriers, compared with only 6 to
10% of newly infected adults [8-10]. The series of immu-
nizations constituting recombinant HBV vaccines are
95% effective at inducing seroimmunity. Although in use
for only 20 years, their duration is likely lifelong [11,12].
Reverse seroconversion of HBV due to medical treat-
ments, such as hematopoietic stem cell transplantation
and high-dose chemotherapy plus rituximab, is an uncom-
mon event that seldom occurs with multiple myeloma as
well. During chemotherapy, amplified viral replication in-
creases DNA polymerase activity, thereby boosting serum
levels of HBV DNA, HBeAb, and HBsAg; reversing
HBsAb titers; and enabling the spread of liver infection
[2]. The immunologic reconstruction that follows cyto-
toxic treatments is marked by massive and rapid immune-
mediated destruction of infected hepatocytes, reflected
clinically in rising AST and ALT levels. Such scenariosmay culminate in serious and even fatal liver disease for a
significant percentage of patients [1-5].
Prior to initiating any cytotoxic or immunosuppressive
therapy, patients should be adequately screened for HBV
infection. Antiviral treatment is advised for HBsAg-
positive states (even if negative for HbeAg) [10,13].
As seen here, HBV reactivation may result from rela-
tively low-dose chemotherapy (melphalan/dexamethasone),
calling for expanded testing in similar circumstances.
Conclusions
This patient (HBsAg-negative/HBsAb-positive status at
baseline) illustrates that HBV reactivation (that is reverse
HBV seroconversion) may develop as an exceedingly rare
consequence of melphalan/dexamethasone therapy for
primary amyloidosis. Comprehensive HBV screening, in-
cluding HBcAg, HBcAb, and HBV DNA serologic test-
ing, is clearly needed in this setting.
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